The 2021 Redburn Gene Therapy Summit, Part 2
CGT Catapult invited to send a speaker for Bioprocessing session: 15 min presentation followed by roundtable discussion
Jonathan Appleby, Chief Scientific Officer
Session 2: Can Bioprocessing Step Up?
- Manufacturing the viral vectors used in gene therapy is an expensive, inefficient process which needs to improve
- Jonathan Appleby, Chief Scientific Officer
- Peter Guterstam, Product Management, Cytiva